Pharsight

Drugs that contain Fluticasone Propionate

1. Armonair Digihaler patents expiration

ARMONAIR DIGIHALER's oppositions filed in EPO
ARMONAIR DIGIHALER Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7540282 TEVA PHARM Reservoir pressure system for medicament inhaler
May, 2023

(10 months ago)

US7540282

(Pediatric)

TEVA PHARM Reservoir pressure system for medicament inhaler
Nov, 2023

(4 months ago)

US9616024 TEVA PHARM Process for preparing a medicament
Sep, 2024

(5 months from now)

US9616024

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(11 months from now)

US9463288 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(1 year, 1 month from now)

US10765820 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(1 year, 1 month from now)

US9463288

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(1 year, 8 months from now)

US10765820

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(1 year, 8 months from now)

US8651103 TEVA PHARM Dry powder inhalation apparatus
Mar, 2028

(4 years from now)

US8651103

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Sep, 2028

(4 years from now)

US10195375 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2031

(6 years from now)

US9731087 TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(7 years from now)

US10022510 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(7 years from now)

US10124131 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(7 years from now)

US9216260 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jun, 2031

(7 years from now)

US10195375

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2031

(7 years from now)

US10022510

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Nov, 2031

(7 years from now)

US10124131

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Nov, 2031

(7 years from now)

US9731087

(Pediatric)

TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
Nov, 2031

(7 years from now)

US9216260

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Dec, 2031

(7 years from now)

US10561808 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

US8978966 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(7 years from now)

US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2032

(7 years from now)

US10561808

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jul, 2032

(8 years from now)

US8978966

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jul, 2032

(8 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2032

(8 years from now)

US9782550 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(11 years from now)

US9782551 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(11 years from now)

US10918816 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Dec, 2035

(11 years from now)

US9782551

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Feb, 2036

(11 years from now)

US9782550

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Feb, 2036

(11 years from now)

US10918816

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Jun, 2036

(12 years from now)

US10569034 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2036

(12 years from now)

US10569034

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Feb, 2037

(12 years from now)

US11351317 TEVA PHARM Drug delivery device with electronics
Feb, 2038

(13 years from now)

US11351317

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Aug, 2038

(14 years from now)

US11357935 TEVA PHARM Drug delivery device with electronics
Sep, 2038

(14 years from now)

US11000653 TEVA PHARM Inhaler
Dec, 2038

(14 years from now)

US11357935

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Mar, 2039

(15 years from now)

US11000653

(Pediatric)

TEVA PHARM Inhaler
Jun, 2039

(15 years from now)

US11344685 TEVA PHARM Drug delivery device with electronics
Sep, 2039

(15 years from now)

US11344685

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Mar, 2040

(16 years from now)

US11439777 TEVA PHARM Drug delivery device with electronics
May, 2040

(16 years from now)

US11464923 TEVA PHARM Inhaler system
Jun, 2040

(16 years from now)

US11173259 TEVA PHARM Drug delivery device with electronics and power management
Jul, 2040

(16 years from now)

US11439777

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Nov, 2040

(16 years from now)

US11464923

(Pediatric)

TEVA PHARM Inhaler system
Dec, 2040

(16 years from now)

US11173259

(Pediatric)

TEVA PHARM Drug delivery device with electronics and power management
Jan, 2041

(16 years from now)

US11266796 TEVA PHARM Inhalation device with integrated electronics
Feb, 2041

(16 years from now)

US11266796

(Pediatric)

TEVA PHARM Inhalation device with integrated electronics
Aug, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

2. Flovent Hfa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7832351 GLAXO GRP LTD Actuation indicator for a dispensing device
Jun, 2023

(8 months ago)

US7832351

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device
Dec, 2023

(2 months ago)

US7500444 GLAXO GRP LTD Actuation indicator for a dispensing device
Feb, 2026

(1 year, 11 months from now)

US7500444

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device
Aug, 2026

(2 years from now)

Market Authorisation Date: 14 May, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

How can I launch a generic of FLOVENT HFA before it's drug patent expiration?
More Information on Dosage

FLOVENT HFA family patents

Family Patents

3. Xhance patents expiration

XHANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8327844 OPTINOSE US INC Nasal delivery method
Oct, 2023

(4 months ago)

US8522778 OPTINOSE US INC Nasal devices
Apr, 2024

(a month from now)

US7975690 OPTINOSE US INC Nasal devices
Dec, 2025

(1 year, 9 months from now)

US10124132 OPTINOSE US INC Nasal delivery
Mar, 2027

(2 years from now)

US11602603 OPTINOSE US INC Nasal delivery devices
Oct, 2028

(4 years from now)

US10076615 OPTINOSE US INC Nasal delivery
Jul, 2029

(5 years from now)

US8550073 OPTINOSE US INC Nasal delivery
Oct, 2029

(5 years from now)

US8978647 OPTINOSE US INC Nasal delivery
Dec, 2030

(6 years from now)

US10252010 OPTINOSE US INC Nasal delivery devices
Feb, 2031

(6 years from now)

US11033696 OPTINOSE US INC Nasal delivery devices
May, 2033

(9 years from now)

US10179216 OPTINOSE US INC Nasal delivery devices
Jul, 2033

(9 years from now)

US10478574 OPTINOSE US INC Nasal administration
Nov, 2033

(9 years from now)

US10076614 OPTINOSE US INC Nasal delivery devices
Oct, 2034

(10 years from now)

US10300229 OPTINOSE US INC Nasal delivery devices
Jul, 2035

(11 years from now)

US11554229 OPTINOSE US INC Nasal administration
Feb, 2036

(11 years from now)

Market Authorisation Date: 18 September, 2017

Treatment: Method of delivering fluticasone propionate to a nasal airway

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

XHANCE family patents

Family Patents